Atom | Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

Due Dates: April 5, 2025 (New/Renewal/Resubmission/Revision) | September 5, 2025 (New/Renewal/Resubmission/Revision)

Funding Amounts: Phase I: up to $500,000 (2 years); Phase II: up to $2.5M (3 years) for approved topics; typical ceiling $1,838,436

Summary: Supports small business-led research to develop innovative products, services, or technologies for the prevention, diagnosis, treatment, or care of Alzheimer's disease and related dementias.

Key Information: Updated March 31, 2025: Aligns with new NIH priorities—review full FOA for changes; clinical trials are optional.

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

Sign in to see full grant listing